0.0000001 meters is roughly the size of the delivery vehicle that could someday replace a whole clean-room manufacturing saga with something closer to a very bossy molecular courier.
That is the puzzle at the center of Lu and colleagues' new review in Signal Transduction and Targeted Therapy: what if we stopped taking T cells out of the patient, engineering them in a lab, expanding them, testing them, freezing them, shipping them back, and then dramatically reintroducing them like contestants returning from a makeover show? What if the body itself could become the CAR-T workshop? Lu et al., 2026
The Old Puzzle Piece: CAR-T Works, But It Is Fussy
CAR-T therapy is one of oncology's stranger magic tricks. Doctors collect a patient's T cells, genetically add a chimeric antigen receptor, or CAR, that helps those cells recognize cancer, then infuse the upgraded immune cells back into the patient. Tiny bodyguards, now with better ID badges.
This has changed care for several blood cancers. But the current ex vivo model, meaning "outside the body," is expensive, slow, and logistically needy. It needs specialized facilities, quality checks, and time. Time is not a cute inconvenience when someone has aggressive lymphoma tapping its watch.
The review's key move is to flip the board: instead of manufacturing CAR-T cells outside the patient, deliver genetic instructions directly into the body and let the patient's own immune system assemble the product in place.
The New Piece: In Vivo CAR-T
In vivo CAR-T uses delivery platforms such as targeted lentiviral vectors or lipid nanoparticles to bring CAR instructions directly to T cells inside the patient. The T cells receive the message, express the CAR, and ideally go hunting for malignant cells.
It is a lovely idea, in the same way "just build the airplane while flying it" is a lovely idea. Elegant? Yes. Relaxing? Absolutely not.
The appeal is obvious. A batch-made vector or nanoparticle could be easier to scale than bespoke cell manufacturing for every patient. Treatment might happen faster. Costs could fall. Access could expand beyond major academic centers with the infrastructure of a small space program. Recent reviews describe this as a major reason the field is moving fast, especially as in vivo platforms enter early clinical development. Bot et al., 2026; Xu et al., 2025
The Delivery Problem, Also Known As "Please Knock On The Right Door"
Here is the catch: delivery is everything.
A viral vector can offer durable CAR expression, but durability comes with regulatory side-eye. If genetic cargo integrates into DNA, developers must track insertional mutagenesis, long-term safety, and off-target transduction. Basically, regulators want to know whether the courier delivered the package to T cells or accidentally left copies in the neighbor's garage.
Lipid nanoparticles have a different personality. They can deliver mRNA without genome integration, which may improve controllability and safety. But mRNA expression is temporary, repeat dosing may be needed, and nanoparticles have historically loved the liver a little too much. The liver is great, but it cannot keep stealing everyone else's mail. Reviews of LNP-based CAR-T engineering highlight both the promise and the unfinished engineering problem: targeting, persistence, immune reactions, and consistent manufacturing all matter. Khawar et al., 2024
Newer work is trying to solve that with targeted nanoparticles, including systems aimed at CD3, CD7, or CD8 on T cells. One 2025 study reported T-cell-specific non-viral DNA delivery using targeted lipid nanoparticles, generating functional CAR-T cells in preclinical models. That is not a clinical victory lap yet, but it is a very interesting puzzle piece clicking into place. Fernandez Bimbo et al., 2025
The Regulatory Plot Twist
Lu and colleagues focus on the part that rarely gets the movie trailer: regulation. But here, regulation is not paperwork confetti. It is the operating system.
Traditional CAR-T quality control can test the final cell product before infusion. In vivo CAR-T does not give you that luxury. The "product" forms inside the patient. That means regulators need different tools: assays for vector targeting, biodistribution, potency, immune activation, persistence, and long-term safety. The dose is not a number of cells anymore. It is a number of vectors or particles, followed by biology doing biology, which is always when biology starts acting like it has tenure.
This is why the authors argue for adaptive regulatory strategies, early engagement with agencies, and international coordination. Translation: do not wait until Phase 3 to ask whether your measurement tools make sense.
Why This Matters
If in vivo CAR-T works reproducibly, it could make cell therapy less like a handcrafted luxury item and more like a scalable medicine. That could matter for blood cancers, solid tumors, autoimmune diseases, fibrosis, and other immune-driven conditions.
But the field still has to answer the hard questions: Can delivery be specific enough? Can expression last long enough, or stop quickly enough? Can immune reactions be controlled? Can every batch behave the same way? Can clinicians monitor a therapy that manufactures itself after infusion?
This paper does not declare the puzzle solved. It does something more useful: it sorts the edge pieces. The picture forming is bold, but the missing pieces are exactly where safety, access, and trust live.
References
-
Lu J, Cui J, Dong J, Yan L, Wang X, Zhou D, Lu S, Wei W. The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects. Signal Transduction and Targeted Therapy. 2026;11:192. https://doi.org/10.1038/s41392-026-02633-4
-
Bot A, Scharenberg A, Friedman K, et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nature Reviews Drug Discovery. 2026;25:116-137. https://doi.org/10.1038/s41573-025-01291-5
-
Xu J, Chen Z, Su L, Ren A, Mei H. In vivo CAR cell therapy: from bench to bedside. Journal of Hematology & Oncology. 2025;18:105. https://doi.org/10.1186/s13045-025-01759-2
-
Khawar MB, Afzal A, Si Y, et al. Steering the course of CAR T cell therapy with lipid nanoparticles. Journal of Nanobiotechnology. 2024;22:380. https://doi.org/10.1186/s12951-024-02630-1
-
Fernandez Bimbo J, van Diest E, Murphy DE, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. Journal for ImmunoTherapy of Cancer. 2025;13:e011759. https://doi.org/10.1136/jitc-2025-011759
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.